Abstract
Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment.
Copyright © 2016. Published by Elsevier Masson SAS.
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenergic alpha-Agonists / therapeutic use*
-
Antidepressive Agents / pharmacokinetics
-
Antidepressive Agents / therapeutic use*
-
Central Nervous System Stimulants / therapeutic use*
-
Depressive Disorder / drug therapy*
-
Dietary Supplements*
-
Dopamine Agonists / therapeutic use*
-
Double-Blind Method
-
Drug Interactions
-
Drug Resistance
-
Drug Therapy, Combination
-
Excitatory Amino Acid Antagonists / therapeutic use*
-
Fatty Acids, Omega-3 / therapeutic use
-
Folic Acid / therapeutic use
-
Food-Drug Interactions
-
Humans
-
Ketamine / therapeutic use*
-
Monoamine Oxidase Inhibitors / pharmacokinetics
-
Monoamine Oxidase Inhibitors / therapeutic use*
-
Randomized Controlled Trials as Topic
-
S-Adenosylmethionine / therapeutic use
Substances
-
Adrenergic alpha-Agonists
-
Antidepressive Agents
-
Central Nervous System Stimulants
-
Dopamine Agonists
-
Excitatory Amino Acid Antagonists
-
Fatty Acids, Omega-3
-
Monoamine Oxidase Inhibitors
-
Ketamine
-
S-Adenosylmethionine
-
Folic Acid